Trials / Completed
CompletedNCT03164603
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- NewLink Genetics Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NLG802 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor |
Timeline
- Start date
- 2017-06-29
- Primary completion
- 2019-04-01
- Completion
- 2019-09-25
- First posted
- 2017-05-23
- Last updated
- 2020-06-04
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03164603. Inclusion in this directory is not an endorsement.